Neurocrine Biosciences, Inc. provided earnings guidance for the full year of 2024. For the year, company expects Net Product Sales of $2,100 million to $2,200 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
134.3 USD | -1.12% | +0.18% | +1.94% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.94% | 13.52B | |
+16.13% | 122B | |
+19.65% | 113B | |
+18.31% | 26.49B | |
-23.84% | 19.4B | |
-18.82% | 16.24B | |
-19.28% | 15.4B | |
-45.95% | 15.15B | |
+63.81% | 14.93B | |
+116.04% | 10.79B |
- Stock Market
- Equities
- NBIX Stock
- News Neurocrine Biosciences, Inc.
- Neurocrine Biosciences, Inc. Provides Earnings Guidance for the Full Year of 2024